Attached files
file | filename |
---|---|
8-K - FORM 8-K - MetaStat, Inc. | mtst8k_june2017.htm |
Exhibit 99.1
MetaStat Announces Completion of Second Milestone of its Pilot
Research Project with Celgene Corporation
Boston, MA., June 19, 2017 -- MetaStat, Inc. (OTCQB:
MTST), a personalized medicine company developing
therapeutic and diagnostic treatment solutions for cancer patients,
announced today it has completed the second milestone under its
pilot research project with Celgene Corporation. To date, MetaStat
has received aggregate milestone
payments of approximately $730,000 from Celgene pursuant to the
terms of the pilot materials transfer
agreement.
“We
are very pleased to have successfully completed the second
milestone and are now working on the next phase of the Celgene
pilot research project,” stated
Douglas A. Hamilton, MetaStat’s President, CEO and
Director.
About MetaStat, Inc.
MetaStat is a biotechnology company focused on discovering and
developing personalized therapeutic and diagnostic treatment
solutions for cancer patients. Our Mena isoform
“driver-based” diagnostic biomarkers also serve as
novel therapeutic targets for anti-metastatic drugs. MetaStat is
developing therapeutic product candidates and paired companion
diagnostics based on a novel approach that makes the Mena isoform
protein a drugable target. Our core expertise includes an
understanding of the mechanisms and pathways that drive tumor cell
invasion and metastasis, as well as drug resistance to certain
targeted therapies and cytotoxic chemotherapies. MetaStat is based
in Boston, MA.
Forward-Looking Statements
This press release contains "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended,
and such forward-looking statements are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. You are cautioned that such statements are subject to a
multitude of risks and uncertainties that could cause future
circumstances, events or results to differ materially from those
projected in the forward-looking statements as a result of various
factors and other risks, including those set forth in the company's
Form 10-K and its other filings filed with the Securities and
Exchange Commission. You should consider these factors in
evaluating the forward-looking statements included herein, and not
place undue reliance on such statements. The forward-looking
statements in this release are made as of the date hereof and the
company undertakes no obligation to update such
statements.
MetaStat, Inc.
Rick Pierce, 617-531-0874
VP Investor Relations
rpierce@metastat.com